Bavarian Nordic to Host Conference Call on PROSTVAC Agreement with Bristol-Myers Squibb
March 04, 2015 07:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KVISTGAARD, Denmark - March 4, 2015 - Bavarian...
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
March 04, 2015 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Bavarian Nordic to receive up to $975 million,...
Bristol-Myers Squibb indgår eksklusivaftale med Bavarian Nordic om PROSTVAC® cancerimmunterapi
March 04, 2015 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Bavarian Nordic modtager op til USD 975 mio.,...
Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium
February 24, 2015 05:24 ET
|
Bavarian Nordic A/S
KVISTGAARD, Denmark, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated overall survival data from an NCI sponsored combination study of...
Bavarian Nordic offentliggør opdaterede overlevelsesresultater fra kombinationsstudie med PROSTVAC og ipilimumab på 2015 Genitourinary Cancers Symposium
February 24, 2015 05:20 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Ca. 20% af de mænd med fremskreden...
Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium
February 24, 2015 05:20 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Approximately 20% of men with advanced prostate...
Bavarian Nordic A/S - Storaktionærmeddelelse
January 27, 2015 01:56 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KVISTGÅRD, Danmark - 27. januar 2015 - Bavarian...
Bavarian Nordic A/S - Major Shareholder Announcement
January 27, 2015 01:56 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KVISTGAARD, Denmark, January 27, 2015 - Bavarian...
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology
January 06, 2015 02:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
First human trial of the MVA-BN® Filo/AdVac®...
Bavarian Nordic offentliggør påbegyndelsen af klinisk fase 1 forsøg med MVA-BN® Filo og AdVac® prime-boost forsøgsvaccinen mod ebola
January 06, 2015 02:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Det første forsøg i mennesker med den...